To Top

Meet Dr. James Berenson of Berenson Oncology in Hollywood

Today we’d like to introduce you to Dr. James Berenson.

Dr. Berenson is the founder of the Institute for Myeloma & Bone Cancer Research (IMBCR) and has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 20 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives.

He serves as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section. He is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. He serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. He also works with many other groups known for their work in multiple myeloma and bone metastases.

After receiving a Bachelor of Science with Distinction from Stanford University, he earned his Doctorate in Medicine from the University of California at San Diego.

Dr. Berenson completed his internship and residency in internal medicine at the University of Utah Medical Center and fellowships in hematology/oncology at the University of California at Los Angeles (UCLA). He is certified by the American Board of Internal Medicine in both internal medicine and medical oncology. He has been affiliated most recently with Cedars-Sinai Medical Center in Los Angeles and served as the Director of the Multiple Myeloma & Bone Metastasis Programs in the Department of Medicine, Division of Hematology/Oncology. Dr. Berenson has performed research as a member of the Departments of Medicine and Biological Chemistry at the UCLA School of Medicine and has served as Chief of Medical Oncology and Cancer Research as well as Director of Research at the Greater Los Angeles Veterans Administration Healthcare Systems. Dr. Berenson has authored and co-authored numerous books, articles, and abstracts in journals including Blood, Cancer, Cancer Research, Journal of Clinical Investigation, Journal of Clinical Oncology, New England Journal of Medicine, and Science.

In addition to his research interests in myeloma and metastatic bone disease, he also studies antibodies, T-cell receptors, cytokines, cancer genes, viruses and blood vessel development. Dr. Berenson has also conducted numerous clinical trials related to the treatment of multiple myeloma and metastatic bone disease. Because he is internationally known for his expertise and accomplishments in these areas, he has also been asked to give numerous lectures and organize many meetings both nationally and internationally.

Dr. Berenson has a private practice which specializes in the treatment of patients with myeloma and metastatic bone disease. He is also President and Chief Executive Officer of Oncotherapeutics, Inc., a corporation that conducts clinical trials related to myeloma and metastatic bone disease as well as other cancers throughout the United States.

Born and raised in Portland, Oregon, Dr. Berenson is married to Debra. They have two children, Shira and Ariana.

Dr. Berenson’s many innovations and successes have included:

  • A Leader in developing techniques that will rid cancer in stem cells for myeloma patients.
  • Discovery of new genes in myeloma bone marrow that will be potential new targets for innovative treatments.
  • Development of a new way to sensitively and accurately measure malignant cells which has provided significant improvements in determining the effects of new drugs as well as treatments for tumors.
  • Discovery of new treatments for myeloma patients that effectively give a much better quality of life for patients through the significant reduction of toxicity.
  • Revolutionized in vivo models making them highly effective to serve as quick ways to optimize drug dosing and treatment techniques for myeloma and bone cancer patients.
  • Identified a new herpes virus that is a promising modality to attack myeloma.
  • Revolutionized research techniques at a genetic level rather than using the traditional protein approach.

Overall, has it been relatively smooth? If not, what were some of the struggles along the way?
As a sole-practitioner in a medical practice specializing in multiple myeloma, every day is a challenge.

Any shoutouts? Who else deserves credit in this story – who has played a meaningful role?
We have an associated non-profit, The Institute for Myeloma and Bone Cancer Research (IMBCR) and with the support of many grateful patients and donors, we are working on finding a cure for multiple myeloma.

Contact Info:

  • Address: 9201 W Sunset Blvd, Ste 300
    West Hollywood, CA 90069
  • Website:
  • Phone: 310-623-1214
  • Email:

Getting in touch: VoyageLA is built on recommendations from the community; it’s how we uncover hidden gems, so if you know someone who deserves recognition please let us know here.

Leave a Reply

Your email address will not be published.

More in